Attending physician, Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, China
Dr. Yong-Ping Lu is an attending physician in the Department of Nephrology at the Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China. His work revolves around metabolic kidney diseases, kidney fibrosis, and the role of gut microbiota in chronic kidney disease (CKD). Dr. Lu holds a Ph.D. from Charité-Universitätsmedizin Berlin and has extensive experience in both clinical and experimental research. He has developed ischemia-reperfusion injury models to study how acute kidney injury (AKI) progresses to CKD. His research has provided significant insights into the mechanisms linking gut microbiota and kidney diseases. Dr. Lu has also established a comprehensive clinical data and specimen repository related to CKD. His leadership in various national and provincial research projects has made him a key figure in advancing nephrology research in China.
Profile
Scopus
Education
Dr. Yong-Ping Lu earned his Ph.D. in Medicine in December 2018 from Charité-Universitätsmedizin Berlin, affiliated with Humboldt-Universität zu Berlin and Freie Universität Berlin. During his doctoral studies, he developed expertise in nephrology and metabolic kidney diseases. His research at Charité focused on understanding the mechanisms underlying kidney fibrosis and chronic kidney disease. After obtaining his Ph.D., he advanced his research career as a postdoctoral fellow at Jinan University from January 2019 to July 2021. During this period, Dr. Lu contributed to pioneering studies in nephrology, including the role of gut microbiota in kidney disease. His academic journey provided him with a solid foundation in both basic and clinical research, making him well-equipped to contribute to cutting-edge research in nephrology. His education laid the groundwork for his current role at Sun Yat-sen University, where he integrates clinical challenges with laboratory research to push the frontiers of kidney disease understanding.
Experience
Dr. Yong-Ping Lu’s professional experience spans both clinical and research settings. Since joining The Seventh Affiliated Hospital, Sun Yat-sen University, in 2021, Dr. Lu has worked as an attending physician in the Department of Nephrology, focusing on metabolic kidney diseases and kidney fibrosis. He has also led numerous research projects investigating the role of gut microbiota in chronic kidney disease (CKD). Prior to this role, he was a postdoctoral fellow at Jinan University from January 2019 to July 2021, where he investigated the molecular mechanisms of kidney diseases and their interactions with metabolic processes. Dr. Lu’s clinical practice and research are deeply integrated, with his work bridging experimental and clinical nephrology. He has developed ischemia-reperfusion injury (IRI) models to study the progression of acute kidney injury (AKI) to CKD. He also oversees a comprehensive database of clinical data and biological specimens related to CKD, strengthening the linkage between research and clinical outcomes.
Awards and Honors
Dr. Yong-Ping Lu has received several prestigious awards and honors throughout his academic and research career. He has been recognized for his exceptional contributions to nephrology and metabolic kidney diseases, including being named the Youth Member of the Nephrology Branch of the Guangdong Medical Association. Additionally, he holds a membership with the Nephrology Branch of the Guangdong Precision Medicine Application Association, reflecting his leadership within the nephrology community. Dr. Lu has led research projects funded by national, provincial, and municipal levels in China, further emphasizing his outstanding scientific and clinical contributions. His work on the gut microbiota and kidney disease has earned him significant recognition in the field of nephrology. Dr. Lu’s impactful research has not only garnered citations but has also influenced clinical practice, earning him positions such as the Editorial Board Member of Clinical Medical Engineering Journal. His achievements continue to make him a leading figure in nephrology research and patient care.
Research Focus
Dr. Yong-Ping Lu’s research primarily focuses on metabolic kidney diseases and kidney fibrosis, with a strong emphasis on understanding the role of gut microbiota in chronic kidney disease (CKD). He has pioneered the establishment of a comprehensive clinical data and specimen repository related to CKD, which aims to uncover the health mechanisms that link gut microbiota with kidney diseases. His studies also explore ischemia-reperfusion injury (IRI) models to investigate how acute kidney injury (AKI) transitions into chronic kidney disease. Dr. Lu’s research integrates both experimental and clinical studies, addressing critical gaps in the understanding of kidney disease progression and treatment. His work has led to insights into metabolic reprogramming in kidney cells and the renoprotective effects of certain drugs. By bridging basic research with clinical application, Dr. Lu strives to develop novel diagnostic and therapeutic strategies to improve outcomes for patients with kidney diseases, particularly those with diabetic nephropathy and CKD.
Publication Top Notes
- Mechanism of the cardioprotective effect of empagliflozin on diabetic nephropathy mice based on proteomics 🧬
- Renoprotective effects of empagliflozin in high-fat diet-induced obesity-related glomerulopathy by regulation of gut-kidney axis 🌿
- A Predictive Model for Diabetic Kidney Disease Based on Inflammatory Gene Signatures and Its Regulatory Network 📊
- The role of microbial metabolites in diabetic kidney disease 🦠
- Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease 🧪
- Anthocyanin improves kidney function in diabetic kidney disease by regulating amino acid metabolism 🍇
- Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy 💉
- SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease 💊